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Introduction
Overweight and obesity have become an epidemic and affect over 2.1 billion individuals worldwide [1] . Among the factors predisposing to the pathophysiological development of obesity, excess dietary energy intake is the most common cause [2] . When energy intake exceeds energy expenditure, excessive cellular lipid accumulation occurs not only in adipose tissue but also in ectopic tissues such as liver [3, 4] . Excessive ectopic lipid deposition often disrupts normal cellular physiological function, which if allowed proceed unchecked will lead to pathological progression [3, 4] . With the progress of obesity, increased hepatic lipogenesis in fatty liver (also known as hepatic steatosis), impaired liver function, and eventually liver failure [5, 6] . It has been estimated that 28.8 million or approximately 19% U.S. adults have fatty liver diseases [7] . As liver is a vital organ which participates in regulating digestion, as coltting), developing anti-obesity agents with hepatoprotective properties has become of Scutellaria baicalensis Georgi (known as huáng qín) is one of important herbs used in traditional Chinese medicine [8] . Both animal and human studies have suggested that Scutellaria baicalensis Georgi antidiabetic and antidyslipidemic properties, and have been used to treat conditions such have indicated that Scutellaria baicalensis contains several bioactive chemical compounds them, baicalin, a polyphenolic compound, is one of the most potent and abundant components [16] . Although few studies have been reported, in vitro and animal experiments from two laboratories have suggested that baicalin may possesses anti-obesity effects, including inhibition of adipogenic pathway in 3T3-L1 preadipocytes and prevention of dyslipidemia in remain unanswered, such as its safety and the therapeutic windows. In addition, the preventive effects of baicalin have been shown in high-fat diet animal model (intervention was initiated before obesity development) [17] , but whether there are therapeutic effects (intervention is used to treat those with obesity) are currently unknown. Investigating the facts of high obesity prevalence worldwide. Therefore, in the present study, three doses of baicalin (100, 200 and 400 mg / kg body weight / day, respectively) were given to obese animals that had been fed with high fat diet for 16 weeks. The safety, therapeutic effects and dose-response of baicalin as well as liver pathological alterations and molecular mechanism were evaluated. Our data suggested that baicalin up to 400 mg/kg/d is safe and can dosedependently decrease body weight, hyperlipidemia and liver steatosis in high fat diet-fed mice, and that liver Ca Cellular Physiology and Biochemistry
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Animal study
China) at the age of 8 weeks, and were acclimatized for one week prior to the experimental use. Mice were two groups: lean control (LC) fed with the normal diet (n = 6) and obesity fed with the high-fat diet (n = 24). The proportion of dietary energy in high fat diet was 40% calories from fat, 42.6% from carbohydrate Engineering (Jiangsu, China). After 16 weeks of high fat diet treatment, mice became obese and body then randomly divided into one of four groups: high-fat diet control (HF) and high-fat diet along with oral administration of three different concentration of baicalin (100, 200 or 400 mg baicalin / kg body weight / day, respectively) for 14 weeks. Baicalin was mixed with 0.5% carboxymethylcellulose sodium solution, a food additive to stabilize the emulsions of baicalin. Both lean control and high-fat diet control mice were carboxymethylcellulose sodium solution was administrated once daily through oral gavage using a syringe with 12 gauge feeding needle. Food and water were given to all mice ad libitum throughout the study. At the end of 30 weeks of experiments, all mice were fasted overnight. Body weight, epididymal fat pad and liver weight were measured. Serum samples were collected for biochemical parameter determination, and liver
Serum biochemical assays
Serum levels of triglycerides, total cholesterol, the amount of cholesterol contained in low-or Shanghai, China).
Hematoxylin and eosin staining and liver steatosis scoring
USA). Hematoxylin and eosin staining was performed according to manufacturer's protocol. Liver steatosis
Oil red O staining
Liver sections were stained with an oil red O staining kit and counterstained with hematoxylin to detect hepatic lipid accumulation following the manufacturer's protocols. Images were captured in a Western blot analysis standard immunoblotting procedure, including incubation with primary antibody overnight at 4°C. The immunocomplexes were visualized via enhanced chemiluminescence, and scanned for further densitometry analysis.
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Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry while their body weight was then gradually increased (Fig. 1A) . Similarly, an attenuation of body weight gain in all HF mice which were also orally given with vehicle or baicalin was observed during this time period (Fig. oral gavage induced an adverse stress in all mice, but mice were able to get acclimated to the procedure. As the attenuation of body weight gain during the accumulated period in four groups of high fat diet-fed mice was not statistically different, a similar stressful level induced by gavage procedure was considered among mice. Baicalin intervention (100, 200
. 1A), but the body weight was not statistically . 1A). All three doses Cellular Physiology and Biochemistry weight in high fat diet group was restored by baicalin to the level comparable to the normal diet controls (Fig. 1C) .
Baicalin attenuates high fat diet-induced hyperlipidemia
baicalin, and higher dosages of baicalin (200 and 400 mg/kg) were able to restore all these hyperlipidemia parameters comparable to .
Baicalin attenuates high fat diet-induced liver dysfunction
restore ALT and AST levels in high fat diet-fed mice to that comparable to the lean controls . 3A-B) 
Baicalin attenuates high fat diet-induced liver steatosis
liver steatosis, as evidenced by the increased number of empty fat vacuoles that were either larger or smaller than hepatocyte nucleus, known as macrovesicular and microvesicular steatosis (Fig. 4A) . The area of steatosis in high fat diet control groups accounted for 43% of hepatic lobules (Fig. 4C) . Baicalin treatment at the lower dosage (100 mg/kg/d) visibly reduced the number of macrovesicular steatosis in high fat-fed mice, but microvesicular steatosis dominantly occupied in the hepatic lobule (Fig. 4A) . Therefore, the total area of steatosis in baicalin 100mg/kg group was decreased but not statistically different from that in the high fat control group (Fig. 4C) . With the increasing dose from 100 to 200 and 400
. 4A and C). Consistent with the data of control group, while reduced dose-dependently by increasing level of baicalin (Fig. 4B) . , 4, 7] . Epidemiological studies have suggested that excess dietary energy intake is one of the most common causes of obesity [1, 2] . Using high fat diet animal model, here we demonstrate that high fat diet-induced obesity and liver steatosis and dysfunction can be diminished by baicalin, a polyphenolic compound found in Scutellaria baicalensis Georgi [8, 16] . Our data suggest that baicalin up to 400 mg/kg/d for 14 weeks was safe for high fat diet-fed mice, and its anti-obesity and hepatoprotective capabilities were increased with the increasing doses (from 100 to 400 mg/kg/d). The hepatoprotective effects of baicalin appears to be associated with the hepatic de novo lipogenesis. The therapeutic potency of baicalin has been extensively studied, which demonstrated high fat diet-induced obesity [17, 26, 27] , our data showed that excess energy intake was and internal organs, including liver and epididymal fat pads (Fig. 1 ) in young animals. To obese animals after 16 weeks of high fat diet ingestion were orally given three different doses of baicalin for additional 14 weeks. Our data suggested that chronic baicalin treatment was able to dose-dependently diminish the parameters of hyperlipidemia, including serum mice and the percentage of liver and epididymal fat pad to body weight (Fig. 1) , suggesting reported studies (an in vitro 3T3-L1 preadipocyte study [18] and a preventive animal study in which baicalin intervention was initiated prior to obesity development [17]) provide However, more pre-clinical and clinical studies are needed to attest its safety, therapeutic
One of the most deteriorative effects of obesity is to cause excessive ectopic lipid deposition, which leads to disrupted cellular physiological function and pathological progression of internal organs [3, 4, 24] . Liver performs critical roles in regulating digestion, homeostasis (such as coltting), and hence is necessary for survival. With increased hyperlipidemia and obesity in high fat diet-fed mice, lipids accumulated within liver cells, and formed fat vacuoles (liposomes), a pathological process also known as steatosis (Fig.  4) . Liver became fatty and gained weight (Fig. 1) . However, these pathological alterations in high fat diet animals can be attenuated with increasing dose of baicalin ( Fig. 1 and 4) , and the improvement in hepatic morphology by baicalin was associated with the decrease of serum Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry levels of alanine transaminase and aspartate transaminase (Fig. 3) , suggesting that baicalin treatment up to 400 mg/kg/d for 14 weeks was safe and able to attenuate obesity-associated developing baicalin as an anti-obesity agent but carrying hepatoprotective properties will of limited liver side effect-free drugs available.
To further understand the therapeutic effects of baicalin on obesity and fatty liver diseases, we next investigated liver Ca 2+ activated protein kinase / acetyl-CoA carboxylase pathway. Excessive hepatic de novo liver diseases [5, 6] . The ACC plays an important role in the biosynthesis of fatty acids by producing substrate malonyl-CoA, and is thought to be a great target of anti-obesity therapy [31] . The enzymatic activity of ACC is regulated via multiple mechanisms, including 33]. The phosphorylation of ACC inhibits its enzymatic activity and is mainly catalyzed by in vitro cell study showed that baicalin can stimulate 26, 27], our data suggested that expression of liver ACC was not altered in obese animals, but phosphorylation were dose-dependently increased by baicalin (from 100 to 200mg/kg), and with higher doses (both 200 and 400 mg/kg/d) they were restored to that comparable . 4), in which baicalin at lower dosage (100 mg/kg/d) was found to predominantly reduce the number of macrovesicular steatosis in high fat-fed mice, while the area of both macrovesicular and microvesicular steatoses . 4). These data were also parallel to the degree of decreased hyperlipidemia and liver weight by increasing dose of baicalin ( Fig. 1 and 2 ) and improved liver function indices ALT and AST (Fig. hepatoprotective and anti-obesity properties of baicalin.
In summary, the data from this study demonstrate that high fat diet-induced obesity, hyperlipidemia, fatty liver disease (steatosis) and hepatic dysfunction can be treated with baicalin. The therapeutic effects of baicalin is dose-dependent and with optimal dose between 200 and 400 mg/kg/d. Up to 400 mg/kg/d is liver safe for high fat diet animals pathway, a key regulator of hepatic de novo lipogenesis, can be inhibited by the increasing dose of baicalin, and may mediate, at least in part, the therapeutic effects of baicalin. This work was supported by a grant provided by Southeast University. The authors assistance. The funder had no role in study design, data collection and analysis, preparation of the manuscript, or decision to publish. All the authors declare that they have no competing interests.
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